CN106620056A - Pharmaceutical composition for treating diabetic retinopathy - Google Patents
Pharmaceutical composition for treating diabetic retinopathy Download PDFInfo
- Publication number
- CN106620056A CN106620056A CN201611133150.5A CN201611133150A CN106620056A CN 106620056 A CN106620056 A CN 106620056A CN 201611133150 A CN201611133150 A CN 201611133150A CN 106620056 A CN106620056 A CN 106620056A
- Authority
- CN
- China
- Prior art keywords
- weight
- pharmaceutical composition
- extract
- ethanol
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating diabetic retinopathy, and a preparation method of the pharmaceutical composition. The pharmaceutical composition is prepared from the following crude drugs: caulis sargentodoxae, herba anotis ingratae, asiaticoside and inulicin according to a proportion. The pharmaceutical composition can be prepared into various preparations according to the conventional preparation technology, and is remarkable in curative effect when being used for treating the diabetic retinopathy.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for treating diabetic retinopathy and
Its preparation method.
Background technology
Diabetes (DM) are to increase the metabolic disease group being characterized with blood sugar, and BDR (DR) is that its is tight
One of complication of weight, is one of retinopathy main in blinding illness in eye.Research shows, the degree of DR and the course of disease of DM, blood
Sugared control level is proportionate.The eyeground pathological changes of DR be mainly microaneurysm, bleeding, ooze out, oedema, capillary are inaccessible, new
Angiogenic propagation etc. and shows as the DPNs such as defect of visual field at ischemic microangiopathies.In recent years, Chinese medicine DR
With improving microcirculation, protection vascular wall, reduce oedema and ooze out and the features such as toxic and side effect is little, increasingly closed
Note, Chinese herb decoction opinion is controlled, and especially to early stage PVR curative effect preferably, advantage is unique.
Three-jaw gold dragon:For Vitaceae Parthenocissus plant parthenocissus himalayana Plancs Parthenocissus himalayana
(Royle)Planch. the complete stool of [ Ampelopsis himalayana Royle ].Autumn, winter harvesting root and stem, cut after cleaning
Piece or segment, dry.Summer, autumn picking leaves, dry.【Nature and flavor】It is pungent;Temperature.【Indication】Dispelling wind and eliminating dampness;Dissipate blood stasis and smoothing collaterals.Main wind
Pain of dampness syndrome;Traumatic injury;Fracture.【Former phytomorph】Parthenocissus himalayana Plancs fallen leaves woody climber.Multi-branched, branch is sturdy, drabon
Color;Tendril is short and branch, and there is sucker on top.The leaflet alternate of palmate 3;The long 5-12cm of common petiole, without hair or hairiness;Blade papery,
Middle leaflet is avette or width drape over one's shoulders needle-like avette, long 6-12cm, wide 2-7cm, and tip is tapering or nearly shape of tail, and base portion wedge shape, side life is little
Leaf is asymmetric, tiltedly avette, and leaflet is smaller compared with the middle of, and edge has substantially and the sawtooth with tip, above without hair, below or along vein
There is thin pubescence;The long 5-6mm of petiolule.Flower both sexes, cyme be often born in the top of brachyplast or with leaf opposite;Bennet is compared with petiole
It is short;Flower light green, 5 numbers 4 are counted sometimes;Calyx shallow disc shape, full edge;Petal Long Circle;Stamen and petal opposite;Floral disc is not obvious;
Style short cylindrical shape, tip often expands discoid after petal comes off.Berry is spherical, ripe time-varying pitchy, has white powder, seed 1-2
.Record in dictionary of medicinal plant.
Common anotis herb:For Rubiaceae vacation plants of Hedyotis common anotis herb Anotis ingrata (wall.) Hook. F.
The herb of [Neanotis yngrata (Wall.ex Hook .f) W.H.Lewis].Summer, autumn receive adopt herb, eliminate soil,
Debris, dry standby.【Nature and flavor】Taste is pungent;It is cool in nature.【Return through】The heart;Liver Channel.【Indication】Clearing liver-fire.Main nameless sores or boils;Mesh
It is crimson swollen;Venomous snake bite.【Former phytomorph】Renascent herb, up to 1m.Stem branch or does not have minority branch, it is upright or under
The sleeping ground in portion.Leaf opposite;Petiole is short;The nearly triangle in stipule bottom, Colaesce is born between two petioles, edge tool fine hair;Blade
, to ovum shape lanceolar, long 4-9cm, wide about 1.8cm, tip is tapering, base portion wedge shape, full edge for papery, oval or long oval,
Two sides is by pubescence.Dichasium basidixed, total bennet and branch have narrow aliform corner angle;Floral white, without obstructing or have short
Stalk;Calyx 4 splits, sliver triangular shape lanceolar, and corolla is about 5mm, and hat manages slightly wider, interior raw pubescence;Stamen 4, flower pesticide exposes corolla
Outward;Ovary is the next, and Room 2, column cap 2 splits.Capsule is subsphaeroidal, slightly flat-sided, wide about 2mm.Seed is little and most, plano-convex, there is little wart point.
The month at florescence 6-7, the fruiting period 7-8 month.Record in dictionary of medicinal plant.
Inulicin(Inulicin):CAS 33627-41-7, molecular formula C17H24O5, molecular weight 308.37.【Medicine
Reason is acted on】Antiulcer, central nervous excitation agent.【Ingredient origin】Feverfew Inula britannica chinensis, inula lineariifolia, inula Britannica
Capitulum.
Asiaticosid(Asiaticoside):CAS 16830-15-2, molecular formula C48H78O19, molecular weight 959.12.【It is raw
Thing activity】Promote wound healing.【Ingredient origin】Centella Centella asiatica.
2 bulk drug chemical constitutions:
Asiaticosid(Asiaticoside))Inulicin(Inulicin).
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of medicine of effectively treatment diabetic retinopathy
Compositions and preparation method thereof.
The present invention adopts the following technical scheme that realization:
The composition and weight portion for making the bulk drug of the pharmaceutical composition of the treatment diabetic retinopathy be:
Three-jaw gold dragon 7060-7080 weight portion common anotis herb 400-410 weight portion asiaticosid 30-34 weight portions Inula britannica chinensis time
Lactone 50-52 weight portions.
The pharmaceutical composition for the treatment of diabetic retinopathy is preferably used in, is by the bulk drug group of following weight portion
Into:
The weight portion of 32 weight portion inulicin of three-jaw gold 405 weight portion asiaticosid of imperial 7070 weight portion common anotis herb 51.
A kind of pharmaceutical composition for treating diabetic retinopathy, it is characterised in that pharmaceutical composition can adopt preparation
Conventional method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for treating diabetic retinopathy, it is characterised in that pharmaceutical composition and chemical drugs or in
The treatment diabetic retinopathy medicine of medicine composition.
A kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy, it is characterised in that make as follows
It is standby:
The composition and weight portion of bulk drug be:Three-jaw gold dragon 7060-7080 weight portion common anotis herb 400-410 weight portion centellas
Glycosides 30-34 weight portion inulicin 50-52 weight portions;
Preparation method:
(1)Three-jaw gold dragon, common anotis herb, asiaticosid, inulicin are taken by bulk drug proportioning, is mixed, use percentage by weight
The ethanol of concentration 37% takes as solvent in 26 DEG C of temperature extractions, and extraction time is 16 times, and each extraction time is 6.8 hours, every time
Solvent load is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative
Density 1.05, filtration, liquid is first washed with water by XAD-2 large pore resin absorption columns, then with the second of weight percent concentration 18%
Alcoholic solution elutes XAD-2 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 18%, reclaims ethanol, and concentration is dry
It is dry, obtain final product extract A;
(2)Take step(1)Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 10 times, carries every time
The time is taken for 0.8 hour, each solvent load is 34 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.08 is concentrated into, is filtered, liquid is first washed with water by H103 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 57% elutes H103 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 57%,
Ethanol is reclaimed, concentrate drying obtains final product extract B;
(3)Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy, it is characterised in that by as follows
It is prepared by step:
The composition and weight portion of bulk drug be:The weight of 405 weight portion asiaticosid of the three-jaw imperial 7070 weight portion common anotis herb of gold 32
Part weight portion of inulicin 51;
Preparation method:
(1)Three-jaw gold dragon, common anotis herb, asiaticosid, inulicin are taken by bulk drug proportioning, is mixed, use percentage by weight
The ethanol of concentration 37% takes as solvent in 26 DEG C of temperature extractions, and extraction time is 16 times, and each extraction time is 6.8 hours, every time
Solvent load is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative
Density 1.05, filtration, liquid is first washed with water by XAD-2 large pore resin absorption columns, then with the second of weight percent concentration 18%
Alcoholic solution elutes XAD-2 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 18%, reclaims ethanol, and concentration is dry
It is dry, obtain final product extract A;
(2)Take step(1)Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 10 times, carries every time
The time is taken for 0.8 hour, each solvent load is 34 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.08 is concentrated into, is filtered, liquid is first washed with water by H103 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 57% elutes H103 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 57%,
Ethanol is reclaimed, concentrate drying obtains final product extract B;
(3)Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy, it is characterised in that pharmaceutical composition can
To prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
A kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy, it is characterised in that pharmaceutical composition with
Chemical drugs or Chinese medicine composition treatment diabetic retinopathy medicine.
Medicine composite for curing diabetic retinopathy is evident in efficacy.
Specific embodiment
Embodiment 1:Pharmaceutical composition for the treatment of diabetic retinopathy and preparation method thereof
Treatment diabetic retinopathy pharmaceutical composition bulk drug composition and weight portion be:Three-jaw gold dragon 7070g mono-
Post perfume 405g asiaticosid 32g inulicin 51g;
Preparation method:
(1)Three-jaw gold dragon, common anotis herb, asiaticosid, inulicin are taken by bulk drug proportioning, is mixed, use percentage by weight
The ethanol of concentration 37% takes as solvent in 26 DEG C of temperature extractions, and extraction time is 16 times, and each extraction time is 6.8 hours, every time
Solvent load is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative
Density 1.05, filtration, liquid is first washed with water by XAD-2 large pore resin absorption columns, then with the second of weight percent concentration 18%
Alcoholic solution elutes XAD-2 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 18%, reclaims ethanol, and concentration is dry
It is dry, obtain final product extract A;
(2)Take step(1)Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 10 times, carries every time
The time is taken for 0.8 hour, each solvent load is 34 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.08 is concentrated into, is filtered, liquid is first washed with water by H103 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 57% elutes H103 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 57%,
Ethanol is reclaimed, concentrate drying obtains final product extract B;
(3)Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2:Pharmaceutical composition for the treatment of diabetic retinopathy and preparation method thereof
Treatment diabetic retinopathy pharmaceutical composition bulk drug composition and weight portion be:Three-jaw gold dragon 7060g mono-
Post perfume 410g asiaticosid 30g inulicin 52g;
Preparation method:
(1)Three-jaw gold dragon, common anotis herb, asiaticosid, inulicin are taken by bulk drug proportioning, is mixed, use percentage by weight
The ethanol of concentration 37% takes as solvent in 26 DEG C of temperature extractions, and extraction time is 16 times, and each extraction time is 6.8 hours, every time
Solvent load is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative
Density 1.05, filtration, liquid is first washed with water by XAD-2 large pore resin absorption columns, then with the second of weight percent concentration 18%
Alcoholic solution elutes XAD-2 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 18%, reclaims ethanol, and concentration is dry
It is dry, obtain final product extract A;
(2)Take step(1)Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 10 times, carries every time
The time is taken for 0.8 hour, each solvent load is 34 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.08 is concentrated into, is filtered, liquid is first washed with water by H103 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 57% elutes H103 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 57%,
Ethanol is reclaimed, concentrate drying obtains final product extract B;
(3)Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3:Pharmaceutical composition for the treatment of diabetic retinopathy and preparation method thereof
Treatment diabetic retinopathy pharmaceutical composition bulk drug composition and weight portion be:Three-jaw gold dragon 7080g mono-
Post perfume 400g asiaticosid 34g inulicin 50g;
Preparation method:
(1)Three-jaw gold dragon, common anotis herb, asiaticosid, inulicin are taken by bulk drug proportioning, is mixed, use percentage by weight
The ethanol of concentration 37% takes as solvent in 26 DEG C of temperature extractions, and extraction time is 16 times, and each extraction time is 6.8 hours, every time
Solvent load is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative
Density 1.05, filtration, liquid is first washed with water by XAD-2 large pore resin absorption columns, then with the second of weight percent concentration 18%
Alcoholic solution elutes XAD-2 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 18%, reclaims ethanol, and concentration is dry
It is dry, obtain final product extract A;
(2)Take step(1)Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 10 times, carries every time
The time is taken for 0.8 hour, each solvent load is 34 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.08 is concentrated into, is filtered, liquid is first washed with water by H103 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 57% elutes H103 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 57%,
Ethanol is reclaimed, concentrate drying obtains final product extract B;
(3)Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4:The preparation of tablet
The pharmaceutical composition 74g of Example 1, adds starch 123g, mixes, and granulation is dried, plus microcrystalline cellulose 50g, stearic acid
Magnesium 5g, mixes, and is pressed into 500, obtains final product medicinal composition tablets.
Embodiment 5:The preparation of capsule
The pharmaceutical composition 83g of Example 2, adds starch 120g, mixes, and granulation is dried, whole grain, adds appropriate magnesium stearate,
Mix, encapsulated 600, obtain final product medicament composition capsule.
Embodiment 6:The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 187g water-baths and boil molten, add the pharmaceutical composition 11g of embodiment 3, fully stir
Mix uniform, with atoleine as cooling agent, put glass tube(4*80cm)In, chilling temperature is 6 DEG C, and drip internal-and external diameter is 7.0/
1.5 (mm/mm), drip is 1.9cm away from liquid level, and drop speed, as optimum condition, with cotton the cold of dripping pill surface is blotted with per point 60 drops
Solidifying agent, obtains final product medicament composition dropping pills.
Experimental example 1:The Experiment on Function research for the treatment of diabetic retinopathy
1 clinical data
1.1 physical data
Case is respectively the hospital of traditional Chinese hospital of Jinan City ophthalmic patient, and 36 patients are with regard to diabetes diagnosis according to the World Health Organization
It is that standard is made a definite diagnosis and meet what ophthalmology branch of Chinese Medical Association in 1984 formulated《Stages of DR standard》, it is
Simple form.Treatment group and control group are each 18, in treatment group man 9, female 9, average age (50.12 ± 6.24) year, blood sugar
(10.18±2.21)mmol/L.In control group man 9, female 9, average age (51.09 ± 7.33) year, blood sugar (9.79 ±
1.68)mmol/L.Random packet, statistical procedures no significant difference.Inspection method:36 patients are before treatment and after treatment
The measure for carrying out eyesight, funduscopy and Hemorheology in 1 month, including:WBV, cholesterol and triglycerides.
1.2 treatment method
Western medicine group:Antidiabetic drug is oral, and according to blood sugar level consumption is adjusted, and Tanakan is oral daily 2 ~ 3;Treatment group:Antidiabetic drug
Orally, combination of oral medication(The pharmaceutical composition of embodiment 1), each 1.7g, 3 times a day, 1 month be 1 course for the treatment of, two groups of medications
It is oral that period hyperpietic gives depressor.
1.3 efficacy determination indexs
1) eyesight:Effective, eyesight is improved more than 3 rows;Take a turn for the better, improve 1 ~ 3 row;It is invalid, do not improve or decline;2) eyeground:It is effective,
Eyeground microaneurysm, bleeding is oozed out area and is disappeared up to more than 1/2;Take a turn for the better, eyeground microaneurysm, bleeding, ooze out area disappear reach
1/4~1/2;It is invalid:Eyeground microaneurysm, bleeding, ooze out and do not disappear or increase;3) change of Hemorheology:WBV, courage
Sterol and triglycerides.
1.4 testing result
The results are shown in Table 1-2.
Change of the medicine composite for curing pure diabetes of table 1 to eyesight
Group | n | It is effective | Take a turn for the better | It is invalid |
Western medicine group | 18 | 3 | 13 | 2 |
Treatment group | 18 | 9# | 8 | 1 |
Note:Compare #P with Western medicine group<0.05.
Change of the medicine composite for curing pure diabetes of table 2 to eyeground
Group | n | It is effective | Take a turn for the better | It is invalid |
Western medicine group | 18 | 6 | 9 | 3 |
Treatment group | 18 | 13# | 4 | 1 |
Note:Compare #P with Western medicine group<0.05.
Claims (8)
1. a kind of pharmaceutical composition for treating diabetic retinopathy, it is characterised in that make the bulk drug of the pharmaceutical composition
Composition and weight portion be:
Three-jaw gold dragon 7060-7080 weight portion common anotis herb 400-410 weight portion asiaticosid 30-34 weight portions Inula britannica chinensis time
Lactone 50-52 weight portions.
2. a kind of pharmaceutical composition for treating diabetic retinopathy according to claim 1, it is characterised in that make this
The composition and weight portion of the bulk drug of pharmaceutical composition be:
The weight portion of 32 weight portion inulicin of three-jaw gold 405 weight portion asiaticosid of imperial 7070 weight portion common anotis herb 51.
3. a kind of pharmaceutical composition for treating diabetic retinopathy according to claim 1, it is characterised in that medicine group
Compound can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or dripping pill.
4. a kind of pharmaceutical composition for treating diabetic retinopathy according to claim 1, it is characterised in that medicine group
The treatment diabetic retinopathy medicine that compound is constituted with chemical drugs or Chinese medicine.
5. a kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy, it is characterised in that make as follows
It is standby:
The composition and weight portion of bulk drug be:Three-jaw gold dragon 7060-7080 weight portion common anotis herb 400-410 weight portion centellas
Glycosides 30-34 weight portion inulicin 50-52 weight portions;
Preparation method:
(1)Three-jaw gold dragon, common anotis herb, asiaticosid, inulicin are taken by bulk drug proportioning, is mixed, use percentage by weight
The ethanol of concentration 37% takes as solvent in 26 DEG C of temperature extractions, and extraction time is 16 times, and each extraction time is 6.8 hours, every time
Solvent load is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative
Density 1.05, filtration, liquid is first washed with water by XAD-2 large pore resin absorption columns, then with the second of weight percent concentration 18%
Alcoholic solution elutes XAD-2 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 18%, reclaims ethanol, and concentration is dry
It is dry, obtain final product extract A;
(2)Take step(1)Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 10 times, carries every time
The time is taken for 0.8 hour, each solvent load is 34 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.08 is concentrated into, is filtered, liquid is first washed with water by H103 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 57% elutes H103 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 57%,
Ethanol is reclaimed, concentrate drying obtains final product extract B;
(3)Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy according to claim 5, its feature
It is to prepare as follows:
The composition and weight portion of bulk drug be:The weight of 405 weight portion asiaticosid of the three-jaw imperial 7070 weight portion common anotis herb of gold 32
Part weight portion of inulicin 51;
Preparation method:
(1)Three-jaw gold dragon, common anotis herb, asiaticosid, inulicin are taken by bulk drug proportioning, is mixed, use percentage by weight
The ethanol of concentration 37% takes as solvent in 26 DEG C of temperature extractions, and extraction time is 16 times, and each extraction time is 6.8 hours, every time
Solvent load is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative
Density 1.05, filtration, liquid is first washed with water by XAD-2 large pore resin absorption columns, then with the second of weight percent concentration 18%
Alcoholic solution elutes XAD-2 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 18%, reclaims ethanol, and concentration is dry
It is dry, obtain final product extract A;
(2)Take step(1)Dregs of a decoction A, with the ethanol of weight percent concentration 48% as solvent, heating and refluxing extraction 10 times, carries every time
The time is taken for 0.8 hour, each solvent load is 34 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.08 is concentrated into, is filtered, liquid is first washed with water by H103 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 57% elutes H103 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 57%,
Ethanol is reclaimed, concentrate drying obtains final product extract B;
(3)Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy according to claim 5, its feature
It is that pharmaceutical composition can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or dripping pill.
8. a kind of preparation method of the pharmaceutical composition for treating diabetic retinopathy according to claim 5, its feature
It is pharmaceutical composition and chemical drugs or Chinese medicine composition treatment diabetic retinopathy medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611133150.5A CN106620056A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for treating diabetic retinopathy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611133150.5A CN106620056A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for treating diabetic retinopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106620056A true CN106620056A (en) | 2017-05-10 |
Family
ID=58825325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611133150.5A Withdrawn CN106620056A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for treating diabetic retinopathy |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106620056A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853125A (en) * | 2018-06-05 | 2018-11-23 | 佳木斯大学附属第医院 | A kind of compound and its preparation method and application for preventing and treating optic nerve injury |
-
2016
- 2016-12-10 CN CN201611133150.5A patent/CN106620056A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108853125A (en) * | 2018-06-05 | 2018-11-23 | 佳木斯大学附属第医院 | A kind of compound and its preparation method and application for preventing and treating optic nerve injury |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106668348A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
CN106620056A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
CN106728476A (en) | Treat the pharmaceutical composition of diabetic retinopathy | |
CN106668125A (en) | Pharmaceutical composition for treating optic atrophy and preparation method of pharmaceutical composition | |
CN106668546A (en) | Pharmaceutical composition for treating ceratitis | |
CN106109927A (en) | A kind of pharmaceutical composition treating chloasma and preparation method thereof | |
CN105535264A (en) | Medicine composition for treating senile encephalatrophy | |
CN105381225A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method thereof | |
CN106540004A (en) | A kind of pharmaceutical composition for treating diabetic retinopathy | |
CN106511545A (en) | Medicinal composition for treating vitreous opacity | |
CN106728422A (en) | It is a kind of to prevent and treat pharmaceutical composition of glaucoma and preparation method thereof | |
CN106620055A (en) | Pharmaceutical composition for treating diabetic retinopathy and preparation method of pharmaceutical composition | |
CN106728473A (en) | A kind of pharmaceutical composition for preventing and treating diabetic retinopathy | |
CN106729032A (en) | Pharmaceutical composition for treating cold in children | |
CN106728467A (en) | A kind of pharmaceutical composition for preventing and treating climacteric metancholia | |
CN106729031A (en) | A kind of pharmaceutical composition for treating cold in children | |
CN106728475A (en) | Prevent and treat pharmaceutical composition of diabetic retinopathy and preparation method thereof | |
CN106822389A (en) | A kind of pharmaceutical composition for preventing and treating ovarian cyst | |
CN106692578A (en) | Pharmaceutical composition for preventing and treating oral ulcer and preparation method of pharmaceutical composition | |
CN106668346A (en) | Pharmaceutical composition capable of preventing and treating thyroid gland diseases | |
CN106728893A (en) | Treat pharmaceutical composition of diabetic retinopathy and preparation method thereof | |
CN106728472A (en) | A kind of pharmaceutical composition for preventing and treating tympanitis | |
CN106692503A (en) | Pharmaceutical composition for prevention and treatment of tuberculosis and preparing method thereof | |
CN106728142A (en) | A kind of pharmaceutical composition for treating optic atrophy | |
CN106668336A (en) | Pharmaceutical composition for treating otitis media |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170510 |
|
WW01 | Invention patent application withdrawn after publication |